...
首页> 外文期刊>Thoracic cancer. >Stage selection for neoadjuvant radiotherapy in non‐cervical esophageal cancer: A propensity score‐matched study based on the SEER database
【24h】

Stage selection for neoadjuvant radiotherapy in non‐cervical esophageal cancer: A propensity score‐matched study based on the SEER database

机译:非宫颈食管癌新辅助放疗的分期选择:基于SEER数据库的倾向评分匹配研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background The effect of neoadjuvant radiotherapy (NRT) was controversial in non‐cervical esophageal cancer. The aim of this study was to identify which stage of non‐cervical esophageal cancer would get benefit from NRT using propensity score matching (PSM) and survival analysis based on the Surveillance Epidemiology, and End Results (SEER) database. Methods A selection process was used for case screening from the SEER database. Seven baseline variables were included in PSM. The survival analysis were based on T stage (T2 and T3) and status of lymph node involvement (N0 and N+) using Kaplan‐Meier method and log‐rank test for comparing the overall survival of patient with NRT plus surgery versus those who with surgery alone (SA). Results A total of 1631 cases were included in this study. After PSM, 225 cases of esophageal squamous cell carcinoma (ESCC) and 606 cases of esophageal adenocarcinoma (EAC) were enrolled in survival analysis. We found that only T3N+ stage of EAC would got survival benefit from NRT ( P =?0.0052), while NRT showed no significant benefit in overall survival in other stages of EAC and ESCC. Conclusions NRT followed by resection had a significant survival benefit in non‐cervical EAC patients with T3N+ stage. For patients with ESCC and other EAC stages, NRT versus SA did not demonstrate a statistical significant survival difference.
机译:背景新辅助放疗(NRT)的疗效在非宫颈食管癌中引起争议。这项研究的目的是使用倾向评分匹配(PSM)和基于监测流行病学和最终结果(SEER)数据库的生存分析来确定非子宫颈食管癌的哪个阶段将从NRT中受益。方法采用选择过程从SEER数据库中筛选病例。 PSM中包含七个基准变量。生存分析基于T期(T 2 和T 3 )和淋巴结受累状况(N 0 和N ) + ),使用Kaplan-Meier方法和对数秩检验比较NRT加手术患者和单纯手术(SA)患者的总体生存率。结果本研究共纳入1631例。 PSM后,对225例食管鳞状细胞癌(ESCC)和606例食管腺癌(EAC)进行了生存分析。我们发现,只有EAC的T 3 N + 阶段才能从NRT中获得生存获益(P =?0.0052),而NRT在其他阶段的总体生存中却没有显着受益EAC和ESCC。结论NRT +切除对非宫颈EAC T 3 N + 分期患者具有明显的生存获益。对于患有ESCC和其他EAC分期的患者,NRT与SA相比无统计学差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号